Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.

Mauriello, Joseph A.; Dhillon, Shamina; Leone, Tina A.; Pakeman, Basil; Mostafavi, Ramin; Yépez, María Clara

doi:10.1136/bjo.80.12.1073

Cited by 44 publications

(15 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Perhaps the peripheral pathophysiology of HS28 makes it more amenable to BTX treatment than other syndromes. The incidence of secondary resistance was also similar to other studies,14, 15, 17, 21 with the lowest incidence in BP and HS (0–3%), higher with CD (4–7%), and highest with writer's cramp (22%). Although many cases of secondary resistance have been shown to be related to the development of antibodies to BTX,29, 30 these have not always been detected 21, 30.…”

Section: Discussionsupporting

confidence: 89%

“…(The number of patients with blepharospasm in our clinic was low because of several local ophthalmologists who also perform BTX injections.) The efficacy of BTX for treatment of CD, HS, and BP in the first 2 years was also comparable to previous studies 4, 9, 13, 17, 18, 21, 26, 27…”

Section: Discussionsupporting

confidence: 88%

“…The overall incidence of primary resistance of 9.1% was similar to other reports,17, 18, 20, 21, 26 but it is interesting to note that this was much lower for HS (2.9%). Perhaps the peripheral pathophysiology of HS28 makes it more amenable to BTX treatment than other syndromes.…”

Section: Discussionsupporting

confidence: 88%

“…Since then, it has gained widespread acceptance as a safe and effective treatment of a wide variety of dystonic and nondystonic involuntary movement conditions 3. Despite numerous reports confirming its efficacy,4–22 few studies have assessed the outcome of patients beyond the initial 3 years 15, 17, 18, 20, 21. Therefore, we reviewed the clinical characteristics and the long‐term outcome of patients over the past 10 years who have ever received BTX in our regional movement disorders clinic.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Long‐term efficacy of botulinum toxin A in treatment of various movement disorders over a 10‐year period

et al. 2002

View full text Add to dashboard Cite

Although botulinum toxin A (BTX) has been licensed in Canada for treatment of various movement disorders since 1990, few clinical studies regarding its long-term efficacy and side effects have been reported. We conducted a retrospective analysis of 235 patients who received BTX from our movement disorders clinic over a 10-year period (January 1990 to December 1999). A total of 2,616 treatment cycles (multiple injections) were administered to 235 patients with cervical dystonia (CD), hemifacial spasm (HS), blepharospasm (BP), and other movement disorders. Substantial benefit at 5 years was seen in most patients (90% in BP, 88% in HS, 63% in CD, 100% in jaw closing and lower limb dystonia, and 56% in writer's cramp). Benefit was maintained for up to 10 years in CD, HS, and BP data, with a 75.8% benefit reported. Twenty-eight percent of patients discontinued treatment during the follow-up period due to a variety of reasons. Of these, 9.1% of patients developed primary resistance, and 7.5% of patients secondary resistance. Adverse effects, mostly minor, developed in 27% of patients at any one time, occurring over 4.5% of treatment cycles. These were most frequently reported in blepharospasm (22 of 36 patients in 40 cycles), followed by hemifacial spasm (21 of 70 patients in 46 cycles), and cervical dystonia (17 of 106 in 28 cycles). Only 1.3% of patients discontinued therapy due intolerable adverse effects. The results show that BTX is a safe and effective treatment of various types of movement disorders, and most side effects are well tolerated. Discontinuation for any reason was also low after 5 years. Efficacy was maintained after long periods of treatment with high degree of patient satisfaction.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 88%

mentioning

confidence: 99%

See 2 more Smart Citations

Long‐term efficacy of botulinum toxin A in treatment of various movement disorders over a 10‐year period

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Orbicularis myokimia treatment requires lower dose injections of the toxin. Response to the treatments with botulinum toxin continues after repeated injections in the majority of cases even when followed up for more than 10 years 8. For patients who are nonresponsive to botulinum toxin A may benefit from botulinum toxin B can be beneficial in treating the spasms 9.…”

Section: Introduction and Historymentioning

confidence: 99%

Noncosmetic periocular therapeutic applications of botulinum toxin

Kaynak-Hekimhan

2010

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

Botulinum toxin blocks acetylcholine release at the neuromuscular junction. The drug which was initially found to be useful in the treatment of strabismus has been extremely effective in the treatment of variety of conditions, both cosmetic and noncosmetic. Some of the noncosmetic uses of botulinum toxin applications include treatment of spastic facial dystonias, temporary treatment of idiopathic or thyroid dysfunction-induced upper eyelid retraction, suppression of undesired hyperlacrimation, induction of temporary ptosis by chemodenervation in facial paralysis, and correction of lower eyelid spastic entropion. Additional periocular uses include control of synchronic eyelid and extraocular muscle movements after aberrant regeneration of cranial nerve palsies. Cosmetic effects of botulinum toxin were discovered accidentally during treatments of facial dystonias. Some of the emerging nonperiocular application for the drug includes treatment of hyperhidrosis, migraine, tension-type headaches, and paralytic spasticity. Some of the undesired side effects of periocular applications of botulinum toxin inlcude ecchymosis, rash, hematoma, headache, flu-like symptoms, nausea, dizziness, loss of facial expression, lower eyelid laxity, dermatochalasis, ectropion, epiphora, eyebrow and eyelid ptosis, lagophthalmos, keratitis sicca, and diplopia.

show abstract

Long-term Enhancement of Botulinum Toxin Injections by Upper-Eyelid Surgery in 14 Patients With Facial Dyskinesias

Mauriello¹,

Keswani²,

Franklin³

1999

Arch Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

Treatment selections of 239 patients with blepharospasm and Meige syndrome over 11 years.

Cited by 44 publications

References 10 publications

Long‐term efficacy of botulinum toxin A in treatment of various movement disorders over a 10‐year period

Long‐term efficacy of botulinum toxin A in treatment of various movement disorders over a 10‐year period

Noncosmetic periocular therapeutic applications of botulinum toxin

Long-term Enhancement of Botulinum Toxin Injections by Upper-Eyelid Surgery in 14 Patients With Facial Dyskinesias

Contact Info

Product

Resources

About